| Name | Title | Contact Details |
|---|
Alcon Tool Co is a Akron, OH-based company in the Business Services sector.
HeartcoR Solutions is an ECG Core Lab providing 24/7 research and clinical trial management services to pharma, medical device and biotech companies worldwide. HeartcoR provides industry leading cardiac event monitoring technology, Holter monitoring technology, and ECG data analysis for every clinical project. Our cardiac event monitoring technologies require minimal investigator, patient/subject education and training. Our web-based project management and data tracking systems provide “around the clock” project and data status and oversight. Our Cardiac Safety Analysis (QT/QTc) systems and procedures follow all current industry guidance. HeartcoR provides industry leading 12 lead diagnostic ECG acquisition technology and ECG data analysis systems for every clinical project. Our web-based information technology provide investigative sites rapid secure data transfer to HeartcoR`s centralized laboratory. HeartcoR provides continuous 24/7 clinical, technical and data support to investigators, trial sponsors and study coordinators to ensure project continuity
ExploraMed is a medical device incubator dedicated to significantly improving patients quality of life through cutting edge, cost effective device solutions.
Ivr Systems Corporation is a Crescent, IA-based company in the Business Services sector.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN